+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East. This observational study aims to understand how luspatercept affects the need for blood transfusions and hemoglobin levels in real-world clinical settings. The study is sponsored by Bristol-Myers Squibb and focuses on adults who have started luspatercept treatment within the past year. Participants receive luspatercept as prescribed according to the product label, with no experimental intervention assigned by the study. The study observes ongoing treatment and collects data retrospectively and prospectively, following participants for up to 144 weeks. Key measurements include changes in transfusion burden, pre-transfusion hemoglobin, and iron levels, among other clinical and healthcare utilization outcomes. During the study, participants provide signed consent and allow researchers to collect medical data relevant to their treatment with luspatercept. Researchers monitor transfusion visits, hemoglobin levels, treatment duration, dose adjustments, and other health indicators. The study includes comprehensive data collection on participants disease characteristics, comorbidities, and treatment history, aiming to provide a detailed understanding of luspatercepts use over nearly three years.

Age: 18Years +All Genders
13 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.

Age: 16Years - 80YearsAll GendersPhase 3
499 locations
R

Actively Recruiting

Researchers are collecting real-world data in the Gulf Cooperation Council GCC countries on patients with hormone receptor-positive HR-positive, HER2-low or HER2-ultralow metastatic breast cancer mBC who have previously been treated with endocrine therapy. The study evaluates patient characteristics, treatment patterns, survival outcomes, and the safety of Trastuzumab Deruxtecan T-DXd to help optimize treatments and improve outcomes for mBC patients in the region. This observational study follows patients who have started treatment with T-DXd as part of their routine care. Eligible participants include female patients aged 18 years or older with confirmed HR-positive metastatic breast cancer classified as HER2-low or HER2-ultralow, who have received at least one prior line of endocrine therapy but no chemotherapy in the metastatic setting. Patients are observed for up to 18 months to assess treatment patterns and safety. Participants will have their health information collected and monitored, including progression-free survival, time to next treatment, safety profiles, and baseline characteristics. Data is gathered through routine clinical visits without intervention from the study team. The study duration extends through March 2029, allowing for long-term observation of treatment outcomes and patient experiences.

Age: 18Years +FEMALE
9 locations
A

Actively Recruiting

Hepatocellular carcinoma HCC is a common and serious cancer worldwide, often linked to cirrhosis caused by hepatitis B or C viruses and steatotic liver disease. This research focuses on understanding the causes, patient and tumor characteristics, treatments, and outcomes of HCC in adults across various countries in the Middle East and North Africa region, where the disease burden is significant. Differences in healthcare resources and access in these countries affect diagnosis and treatment outcomes. The study collects and reviews existing medical records of adult patients diagnosed with HCC between 2015 and 2023 in the MENA region. It examines details such as patient demographics, tumor features, risk factors, and treatment methods used. This observational study uses secondary data collection without administering any new treatments or interventions. Participants will have their clinical information, laboratory tests, imaging results, and treatment histories analyzed from medical records. The research team will assess outcomes like overall survival and progression-free survival over an eight-year period. Data completeness and follow-up for at least six months are required for inclusion. The study aims to improve understanding of HCC management and outcomes in this region through detailed data review.

All AgesAll Genders
17 locations
I

Actively Recruiting

Researchers are observing patients with Gaucher disease in the International Collaborative Gaucher Group ICGG Gaucher Registry to understand the diseases variability, progression, and natural history. The study aims to help guide treatment decisions and improve patient care by providing data on patient outcomes and the long-term effectiveness of treatments like imiglucerase and eliglustat. There is also a Gaucher Pregnancy Sub-registry focusing on pregnancy outcomes and infant growth in women with Gaucher disease. Participants in the Registry do not receive experimental treatments but continue with their usual clinical assessments and care as determined by their physicians. The Pregnancy Sub-registry collects data from pregnant women with Gaucher disease, including medical and obstetric history, pregnancy, birth details, and infant growth up to 36 months postpartum. Both registries do not involve any experimental interventions and support standard care practices. During the study, participants undergo routine clinical assessments and provide medical data as part of their ongoing care. Data collected includes patient outcomes, monitoring recommendations, and pregnancy-related information when applicable. The studys primary outcomes include generating monitoring guidelines for Gaucher disease and tracking pregnancy and infant growth outcomes. The registry is ongoing and international, with data collected over several decades to enhance understanding and optimize care for Gaucher disease.

All AgesAll Genders
317 locations
R

Actively Recruiting

Researchers are evaluating whether early endovascular thrombectomy EVT combined with standard anticoagulation improves outcomes compared to anticoagulation alone in adults with severe cerebral venous sinus thrombosis CVST. This multicenter, randomized, open-label trial focuses on patients aged 18 to 65 presenting within 14 days of symptom onset with imaging-confirmed CVST and markers of severity, aiming to address the lack of strong evidence for EVT in this condition, especially in the Middle East, North Africa, and South Asia regions. Participants are randomly assigned to one of two groups the intervention arm receiving EVT within 24 hours plus standard anticoagulation, and the control arm receiving anticoagulation alone. EVT techniques include mechanical thrombectomy, aspiration, or balloon-assisted methods. Anticoagulation consists of intravenous heparin or low-molecular-weight heparin followed by oral anticoagulants for 3-12 months. The study spans approximately 42 months, with 18 months for enrollment and 12 months follow-up for the last patient. Participants will undergo assessments at 30, 90, and 180 days after randomization, including clinical evaluations like the modified Rankin Scale and NIH Stroke Scale, quality of life questionnaires, cognitive testing, and imaging at 90 days. Researchers will monitor functional independence at 12 months as the primary outcome, along with secondary outcomes such as recanalization rates, mortality, clinical improvement timing, quality of life, cognitive function, and seizure frequency. Safety is overseen by an independent board with interim analyses planned throughout enrollment.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
14 locations
S

Actively Recruiting

Researchers are comparing two types of dressings, polyurethane foam Pink Pad and Mepilex Border Sacrum dressings, to prevent pressure ulcers in patients undergoing cardiac surgery at King Abdullah Medical City. The study focuses on patients at risk for pressure ulcers, using standard hospital protocols based on international guidelines to assess risk and provide prevention. This randomized clinical trial aims to evaluate which dressing may better help prevent pressure ulcers during surgery, especially for patients positioned in ways that increase risk, such as the Trendelenburg position. The study involves two intervention groups one using a single-use polyurethane foam system including a pink foam pad and related supports, and the other using self-adherent multilayer foam dressings applied to the sacrum. Both interventions are applied by operating room nurses during surgery. Patients will be examined by the wound management team after surgery and again at 3 and 7 days post-operation. Dressings are removed after 7 days or earlier if clinically needed. If patients are discharged sooner, they are examined before discharge. Follow-up lasts up to 7 days post-operation. Participants will be monitored through scheduled examinations and assessments by the wound management team to check for pressure ulcer development. The study measures the incidence of pressure ulcers within 7 days after surgery as its primary outcome. Any patient unable to continue due to death or changes in care setting will be excluded. Researchers will use risk assessment scales and clinical evaluations to track outcomes, ensuring patient safety and adherence to hospital protocols throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
1 location
I

Actively Recruiting

Researchers are conducting a global, multicenter, and long-term observational study called the Pompe Disease Registry to track the natural history and outcomes of Pompe disease in patients, whether they are receiving treatment or not. This registry aims to improve understanding of the diseases variability, progression, and identification to better guide therapeutic interventions and patient care. The registry collects data from patients diagnosed with Pompe disease to characterize the disease population and evaluate the long-term effectiveness of alglucosidase alfa. It serves multiple purposes, including fulfilling regulatory commitments, supporting product development and reimbursement, and enabling other research and non-research uses. Participants provide information over many years, up to 30 years, helping researchers understand the diseases manifestations and progression. The registry gathers data that assists the medical community in developing monitoring recommendations and producing patient outcome reports to optimize care. Participation involves ongoing data collection but does not include experimental treatments or interventions.

All AgesAll Genders
282 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of different physical therapy delivery methods for adults aged 20 to 40 years who have had chronic non-specific neck pain lasting three months or more. The study compares tele-rehabilitation, face-to-face exercises, and a mixed model combining both approaches to find out which best reduces neck pain intensity and disability. It also examines differences in neck movement, fear of movement, patient satisfaction, and adherence to exercise programs. Participants are randomly assigned to one of three groups tele-rehabilitation with live video-guided sessions, traditional in-person supervised exercises, or a hybrid model alternating weekly between face-to-face and tele-rehabilitation sessions. Each group follows a structured exercise plan lasting six weeks, with sessions three times a week lasting 45 to 60 minutes. The program progresses through phases focusing on mobility, strengthening, endurance, and functional training. Throughout the study, participants complete assessments before starting, immediately after the 6-week intervention, and at 3 months follow-up. These include measures of functional disability, neck pain intensity, range of motion, fear of movement, patient satisfaction, and adherence to treatment. The study collects data continuously during the intervention period and monitors outcomes to compare the impact of each delivery model.

Age: 20Years - 45YearsAll GendersPhase Not Applicable
2 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of zinc oxide compared to moist exposed wound ointment MEBO in treating second stage pressure ulcers. This randomized controlled trial aims to determine which topical treatment better supports healing of these ulcers, which are common in patients with prolonged pressure on the skin. The study is sponsored by King Abdullah Medical City and uses a validated wound assessment tool to measure healing progress. Participants will be randomly assigned to one of two groups one receiving topical zinc oxide twice daily every 12 hours, and the other receiving topical MEBO ointment with the same frequency. The treatment period will last up to one month or until the ulcer completely heals. Daily examinations will be conducted to monitor wound status using the Bates-Jensen Wound Assessment Tool BWAT. During the study, participants will undergo daily wound assessments until healing is complete or for a maximum of 30 days. Researchers will collect data on wound healing and recovery time. The study includes regular monitoring to track treatment effects and safety. Participation involves applying the assigned ointment twice daily and attending daily evaluations throughout the treatment period.

Age: 18Years +All GendersPhase 4
2 locations